Re-engineering of the human CYP4B1 enzyme based on the rabbit homolog CYP4B1 yielded an efficient activator of 4-IPO in HepG2 human hepatoma cells (Table 1; Supplementary Table S1), making it a candidate for liver and lung cancer therapy. This evidence concerns the gene CYP4B1 and hepatocellular carcinoma.